Behind the Mask of Tremors: What PRISM Reveals About Parkinson’s Across Europe

Parkinson’s disease is often thought of as a condition of shaky hands and stiff limbs, but the truth runs much deeper. The PRISM study, short for Parkinson’s Real-world Impact Assessment, reveals the full and often messy picture of what life is really like for people with Parkinson’s and their carers across Europe. Instead of focusing on tidy clinical trials, it dives into everyday reality — the challenges, the emotional toll, and the practical burdens that shape daily life with this complex disease. The study gathered data from six European countries — France, Germany, Italy, Portugal, Spain and the United Kingdom — between April and July 2019. A total of 861 people with Parkinson’s and 256 carers completed detailed online questionnaires about their symptoms, treatments, quality of life, relationships, and caregiving strain. It was not designed to track changes over time, but rather to capture a snapshot of what living with Parkinson’s looks like right now. The people who took part were, on average, 65 years old and had been living with the disease for nearly eight years, though this varied from country to country. In Germany, for example, participants were a little younger, averaging about 62 years old, while in France they were closer to 69. Men made up just over half the group. The age at diagnosis also differed — German participants tended to be diagnosed earlier, around 54 years old, while the French were diagnosed closer to 60. In the UK, the average disease duration was about six years, compared with nine and a half years in France. These differences matter because both age and how long someone has lived with Parkinson’s influence not just their symptoms, but also the treatments they receive and the level of support they need. One of the clearest messages from PRISM is that Parkinson’s is far more than a movement disorder. Participants reported an average of nearly thirteen non-motor symptoms each — issues that don’t involve movement but often cause enormous distress. Sleep problems, urinary urgency, low mood, anxiety, sexual difficulties, pain and fatigue were among the most common complaints. These symptoms can easily overshadow tremor or stiffness, yet they’re often underplayed in medical appointments focused on visible movement. Most participants also lived with other health conditions — things like heart disease, high blood pressure, or arthritis. These extra burdens complicate life further and make managing Parkinson’s even tougher. When it came to quality of life, the numbers were sobering. Using the PDQ-39 questionnaire, which measures how Parkinson’s affects day-to-day living, the median score was 29 out of 100, a sign of clear impairment. Mobility problems were particularly troublesome, but the impact rippled into every part of life. Around seven in ten said Parkinson’s had strained their family relationships, and more than sixty percent reported cutting down on daily activities over the previous year. Work was another casualty. Although many participants were already at or near retirement age, Parkinson’s clearly pushed some to leave work early. About twenty-eight percent said they had retired ahead of schedule because of their condition, and nearly a third of those still working had reduced their hours. Other research backs this up, showing that only about a quarter of people with Parkinson’s remain employed ten years after diagnosis. One finding that raised eyebrows was how common impulse control problems were. About forty-five percent of people reported at least one impulsive behaviour, such as compulsive shopping, gambling, binge eating or hypersexuality. These are often linked to dopamine-based medications used in Parkinson’s treatment, and they can create chaos in personal and financial life if left unchecked. Treatment patterns across Europe turned out to be surprisingly inconsistent. Levodopa, the gold-standard Parkinson’s medication, was used by nearly eighty-six percent of participants, but only about twenty-two percent took it on its own without other drugs. In Germany, just over eight percent were on levodopa alone, while in the UK nearly thirty-eight percent were. A follow-up analysis showed that age, how long someone had Parkinson’s, and the country they lived in were all strong predictors of whether they were prescribed levodopa on its own or as part of a cocktail of drugs. Older people were more likely to be on levodopa alone, while those who had lived with Parkinson’s for longer tended to take more complex combinations. Germans were much less likely than others to be on levodopa monotherapy, while people in the UK were far more likely to be. Beyond levodopa, many used combinations of other treatments such as dopamine agonists, MAO-B inhibitors and COMT inhibitors. The reasons for switching or stopping these therapies varied, from side effects to cost to lack of benefit. What PRISM makes clear is that geography influences treatment almost as much as medical need. Local healthcare systems, prescribing habits, and access to certain drugs seem to shape what people actually receive. The toll on carers was unmistakable. Most carers were women, usually the spouse or partner of the person with Parkinson’s. On average they reported a mild to moderate burden, scoring about twenty-seven on the Zarit Burden Interview — a scale that measures stress and strain. Nearly half said Parkinson’s had damaged their intimacy or sexual relationship. A deeper look at the data revealed which factors made caring hardest. Carer strain rose sharply when the person with Parkinson’s had poor quality of life, when the carer spent long hours on care, when the person was older, when impulse control or hypersexual behaviours were present, and when money was tight. The emotional cost of seeing a partner change before your eyes can be immense, and the data show that supporting carers is not optional — it is central to good Parkinson’s care. Healthcare use was heavy too. Almost everyone — over ninety-six percent — had seen a specialist in the past year. About a quarter had been to the emergency department, and one in five had been admitted to hospital. This paints a picture of Parkinson’s as a condition that demands ongoing, hands-on care from health systems, well beyond routine clinic visits. PRISM’s strength lies in its breadth. It captured a large, diverse sample from across Europe and went well beyond motor symptoms to include mental health, carer experience and social impact. But there are limits. Because it was an online survey, people with severe Parkinson’s or limited internet access may be under-represented. It gives a snapshot rather than a timeline, so it cannot show how symptoms and treatments evolve. And self-reported data always carry some risk of memory errors or bias. Even with those caveats, PRISM offers a powerful reality check. It reminds us that non-motor symptoms are not extras — they are central to how people live with Parkinson’s. It shows that treatments vary widely by country, often for reasons unrelated to medical need. It highlights the quiet endurance of carers, whose own wellbeing deserves just as much attention. And it underscores the pressure Parkinson’s places on health systems, not just in terms of cost, but in the human toll of time, care and resilience. What PRISM ultimately delivers is a map of lived experience — a candid look behind the mask of tremors. It shows the parts of Parkinson’s that don’t always make it into medical charts: the exhaustion, the sleepless nights, the strained relationships, and the love that holds it all together. By exposing those realities, the study gives doctors, policymakers and families alike the insight they need to do better — to treat not just the symptoms, but the whole story of Parkinson’s.